First documented isolation of vancomycin-resistant Enterococcus faecium in Sweden.
In recent years enterococci, and Enterococcus faecium in particular, have emerged as important nosocomial pathogens. Of major concern is the increasing antimicrobial resistance to traditionally used agents such as ampicillin, gentamicin and vancomycin. We present a patient with prosthetic heart valves colonized with vancomycin-resistant E. faecium. This is the first reported isolation of vancomycin-resistant E. faecium in Sweden.
Melhus
A
A
Department of Medical Microbiology, Lund University, Malmö General Hospital, Sweden.
Tjernberg
I
I
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy / Q000209:etiology; D004352:Drug Resistance, Microbial; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000209:etiology; D016984:Enterococcus faecium / Q000187:drug effects* / Q000302:isolation & purification; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy* / Q000209:etiology; D006350:Heart Valve Prosthesis / Q000009:adverse effects; D006801:Humans; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D008943:Mitral Valve; D013548:Sweden; D014640:Vancomycin / Q000008:administration & dosage / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D014640:Vancomycin